Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (7): 44-49.doi: 10.6040/j.issn.1671-7554.0.2019.507
WANG Zhao
CLC Number:
| [1] Trottestam H, Horne A, Aricò M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: longterm results of the HLH-94 treatment protocol [J]. Blood, 2011, 118(17): 4577-4584. [2] Johnson TS, Terrell CE, Millen SH, et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis [J]. J Immunol, 2014, 192(1): 84-91. [3] Arca M, Fardet L, Galicier L, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide [J]. Br J Haematol, 2015, 168(1): 63-68. [4] Bergsten E, Horne A, Arico M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study [J]. Blood, 2017, 130(25): 2728-2738. [5] Ehl SA, von Bahr Greenwood T, Hines M, et al. Recommendations for the use of etoposide-based therapy and bone marrow transplantations for the treatment of HLH: consensus statements by the HLH steering committee of the histiocyte society [J]. J Allergy Clin Immunol Pract, 2018, 6(5): 1508-1517. [6] Miyahara M, Sano M, Shibata K, et al. B-cell lymphoma-associated hemophagocytic syndrome: clinicopathological characteristics [J]. Annals of Hematol, 2000, 79(7): 378-388. [7] Shin HJ, Chung JS, Lee JJ, et al. Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis [J]. J Korean Med Sci, 2008, 23(3): 439-444. [8] Hu Y, Xu J, Wang L,et al. Treatment of hemophagocytic lymphohistiocytosis with cyclophosphamide, vincristine, and prednisone [J]. Swiss Med Wkly, 2012, 142: 13512. doi: 10.4414/smw.2012.13512. [9] Wang Y, Huang W, Hu L, et al. Multi-center study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis [J]. Blood, 2015, 126(19): 2186-2192. [10] La Rosée P. First prospective clinical trial in adult HLH [J]. Blood, 2015, 126(19): 2169-2171. [11] 噬血细胞综合征中国专家联盟,中华医学会儿科学分会血液学组. 噬血细胞综合征诊治中国专家共识[J]. 中华医学杂志, 2018, 98(2): 91-95. [12] 中国抗癌协会淋巴瘤专业委员会. 淋巴瘤相关噬血细胞综合征诊治中国专家共识[J]. 中华医学杂志, 2018, 98(18): 1389-1393. [13] Wang J, Wang Y, Wu L, et al. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis [J]. J Hematol Oncol, 2016, 9(1): 84. [14] Mahlaoui N, Ouachée-Chardin M, de Saint Basile G,et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients [J]. Pediatrics, 2007, 120(3): 622. [15] Matsuda K, Toyama K, Toya T, et al. Reactivation of hemophagocytic lymphohistiocytosis triggered by antithymocyte globulin [J]. Intern Med, 2018, 57(4): 583-586. [16] Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis [J]. Nat Rev Clin Oncol, 2010, 7(7): 415-420. [17] Keith MP, Pitchford C, Bernstein WB. Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus [J]. J Clin Rheumatol, 2012, 18(3): 134-137. [18] Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab [J]. Pediatr Blood Cancer, 2013, 60(1): 101-109. [19] Wohlfarth P, Agis H, Gualdoni GA, et al. Interleukin 1 receptor antagonist Anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically Ill adult patients with hemophagocytic lymphohistiocytosis [J]. J Intensive Care Med, 2017, 1: 885066617711386. doi: 10.1177/0885066617711386. [20] Divithotawela C, Garrett P, Westall G, et al. Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor-anakinra [J]. Respirol Case Rep, 2016, 4(1): 4-6. [21] Savage E, Wazir T, Drake M, et al. Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still's disease successfully treated with tocilizumab [J]. Rheumatology(Oxford), 2014, 53(7): 1352-1353. [22] Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy [J]. Blood, 2013, 121(26): 5154-5157. [23] Watanabe E, Sugawara H, Yamashita T, et al. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset still's disease: a case-based review [J]. Case Rep Med, 2016, 2016: 5656320. doi: 10.1155/2016/5656320. [24] Jordan MB, Hildeman D, Kappler J, et al. An animal model of hemophagocytic lymphohistiocytosis(HLH): CD8+ T cells and interferon gamma are essential for the disorder [J]. Blood, 2004, 104(3): 735-743. [25] Canna SW, Wrobel J, Chu N, et al. Interferon-gamma mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice [J]. Arthritis Rheum, 2013, 65(7): 1764-1775. [26] Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways [J]. Growth Factors, 2012, 30(2): 88-106. [27] Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis [J]. Blood, 2016, 127(13): 1666-1675. [28] Maschalidi S, Sepulveda FE, Garrigue A, et al. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice [J]. Blood, 2016, 128(1): 60-71. [29] Broglie L, Pommert L, Rao S, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis [J]. Blood Adv, 2017, 1(19): 1533-1536. [30] Sin JH, Zangardi ML. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report [J]. Hematol Oncol Stem Cell Ther, 2017, 17: 30090. doi: 10.1016/j.hemonc. [31] Wang J, Wang Y, Wu L, et al. Splenectomy as a treatment for adults with relapsed hemophagocytic lymphohistiocytosis of unknown cause [J]. Ann Hematol, 2015, 94(5): 753-760. [32] Carmo M, Risma KA, Arumugam P, et al. Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency [J]. Molecular Therapy, 2014, 23(4): 737-745. |
| [1] | HAN Jing, JIA Chunling. Effects of periodontal basic therapy on postoperative pneumonia in patients with lung cancer before thoracic surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 113-118. |
| [2] | LEI Da-peng,LI Xue-zhong,XU Feng-lei,PAN Xin-liang,LIN Guo-jing,XUE Wei-guo,LI Chun-yang. Effect of fexofenadine hydrochloride sustained capsule for seasonal allergic rhinitis: a doubleblind, randomized, comparative multicenter trial [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(8): 819-822. |
|
||
